1. Home
  2. DMAC vs CAN Comparison

DMAC vs CAN Comparison

Compare DMAC & CAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DMAC
  • CAN
  • Stock Information
  • Founded
  • DMAC 2000
  • CAN 2013
  • Country
  • DMAC United States
  • CAN Singapore
  • Employees
  • DMAC N/A
  • CAN N/A
  • Industry
  • DMAC Biotechnology: Pharmaceutical Preparations
  • CAN Semiconductors
  • Sector
  • DMAC Health Care
  • CAN Technology
  • Exchange
  • DMAC Nasdaq
  • CAN Nasdaq
  • Market Cap
  • DMAC 310.1M
  • CAN 330.5M
  • IPO Year
  • DMAC N/A
  • CAN 2019
  • Fundamental
  • Price
  • DMAC $6.87
  • CAN $0.81
  • Analyst Decision
  • DMAC Strong Buy
  • CAN Strong Buy
  • Analyst Count
  • DMAC 3
  • CAN 6
  • Target Price
  • DMAC $12.33
  • CAN $2.50
  • AVG Volume (30 Days)
  • DMAC 448.5K
  • CAN 25.3M
  • Earning Date
  • DMAC 11-12-2025
  • CAN 08-14-2025
  • Dividend Yield
  • DMAC N/A
  • CAN N/A
  • EPS Growth
  • DMAC N/A
  • CAN N/A
  • EPS
  • DMAC N/A
  • CAN N/A
  • Revenue
  • DMAC N/A
  • CAN $345,360,000.00
  • Revenue This Year
  • DMAC N/A
  • CAN $90.25
  • Revenue Next Year
  • DMAC N/A
  • CAN $42.94
  • P/E Ratio
  • DMAC N/A
  • CAN N/A
  • Revenue Growth
  • DMAC N/A
  • CAN 82.40
  • 52 Week Low
  • DMAC $3.19
  • CAN $0.53
  • 52 Week High
  • DMAC $7.49
  • CAN $3.27
  • Technical
  • Relative Strength Index (RSI)
  • DMAC 63.84
  • CAN 59.68
  • Support Level
  • DMAC $6.83
  • CAN $0.77
  • Resistance Level
  • DMAC $7.41
  • CAN $0.85
  • Average True Range (ATR)
  • DMAC 0.43
  • CAN 0.04
  • MACD
  • DMAC 0.03
  • CAN 0.01
  • Stochastic Oscillator
  • DMAC 73.62
  • CAN 77.32

About DMAC DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.

About CAN Canaan Inc.

Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment and the supplier of the overall scheme for computer software and hardware of digital blockchain. The revenues of the company are derived from the sales of Bitcoin mining machines and related parts and accessories. Geographically, the company derives its maximum revenue from United States.

Share on Social Networks: